Myoblast Transplantation for Cardiac Repair: A Clinical Perspective

The incidence of heart failure is achieving epidemic proportions. Adult human myocytes cannot regenerate because these cells do not reenter the cell cycle. In patients with heart failure, myoblast transplantation is emerging as a potential therapeutic option to augment the function of remaining myoc...

Full description

Saved in:
Bibliographic Details
Published in:Molecular therapy 2004-01, Vol.9 (1), p.14-23
Main Authors: Haider, Husnain Kh, Tan, Alvin C.K, Aziz, Salim, Chachques, Juan C, Sim, Eugene K.W
Format: Article
Language:English
Subjects:
Angiogenesis
Animals
Asia - epidemiology
cardiac
Cardiac Output, Low - epidemiology
Cardiac Output, Low - etiology
Cardiac Output, Low - therapy
Cardiomyocytes
Cardiovascular disease
Cell cycle
Cell Transplantation - adverse effects
Cell Transplantation - mortality
clinical
Clinical Trials, Phase I as Topic
Coronary vessels
Europe - epidemiology
Gene therapy
Growth factors
Heart failure
Heart transplants
Hospitals
human
Humans
Ischemia
Mortality
myoblast
Myoblasts, Skeletal - physiology
Myoblasts, Skeletal - transplantation
Stem cells
transplantation
Transplantation, Autologous
United States - epidemiology
Vascular surgery
Vein & artery diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The incidence of heart failure is achieving epidemic proportions. Adult human myocytes cannot regenerate because these cells do not reenter the cell cycle. In patients with heart failure, myoblast transplantation is emerging as a potential therapeutic option to augment the function of remaining myocytes. Both skeletal myoblasts and autologous bone marrow cell transplantation, after intensive preclinical experimental animal studies, have entered phase I safety studies in humans. Most of these clinical trials have involved small groups of patients and cell transplantation was carried out as an adjunct to coronary revascularization. Preliminary results show that the procedure is safe and leads to improved myocardial function. This paper reviews and summarizes the outcome of these phase I trials involving skeletal myoblast transplantation.
ISSN:1525-0016
1525-0024
DOI:10.1016/j.ymthe.2003.10.009